Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention

Infectious Agents and Cancer

Volumn 3, Issue 1, 2008, Pages

  Barzon, Luisa ^a   Giorgi, Colomba ^b   Buonaguro, Franco M ^c   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PLACEBO; SILGARD; UNCLASSIFIED DRUG; VIRUS DNA; WART VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER SCREENING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CYTOLOGY; DNA INTEGRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FAMILY PLANNING; FATIGUE; FETUS DEATH; FEVER; FOLLOW UP; GOVERNMENT; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; ITALY; MYALGIA; PAPANICOLAOU TEST; PATHOGENESIS; PRACTICE GUIDELINE; PRECANCER; PREVENTIVE MEDICINE; PROTEIN EXPRESSION; REFERENCE DATABASE; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIETY; SPONTANEOUS ABORTION; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VIROLOGY; VIRUS EXAMINATION; VIRUS INFECTION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

EID: 58549116918     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-3-14     Document Type: Review

References (161)

1. IARC Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses. World Health Organization, International Agency for Research on Cancer, Lyon: IARC 2007 90
2. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. J Ferlay F Bray P Pisani DM Parkin, IARC CancerBase No. 5 version 2.0 Lyon: IARC Press 2004
3. Cancer incidence in five continents. DM Parkin SL Whelan J Ferlay L Teppo DB Thomas editors, Lyon: IARC Scientific Publications No. 155 IARC 2002 III
4. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. M Arbyn P Autier J Ferlay, Ann Oncol 2007 18 1425 1427 10.1093/annonc/mdm398 17693659
5. Cervical cancer. I tumori in Italia - Rapporto 2006, e&p anno 30 gennaio-febbraio 2006 suppl. 2
6. SEER Cancer Statistics Review, 1975-2002. LAG Ries MP Eisner CL Kosary BF Hankey BA Miller L Clegg A Mariotto EJ Feuer BK Edwards editors, Bethesda, MD: National Cancer Institute 2005
7. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. M Sant T Aareleid F Berrino M Bielska Lasota PM Carli J Faivre P Grosclaude G Hédelin T Matsuda H Möller T Möller A Verdecchia R Capocaccia G Gatta A Micheli M Santaquilani P Roazzi D Lisi EUROCARE Working Group, Ann Oncol 2003 14 Suppl. 5 v61 118 10.1093/annonc/mdg754 14684501
8. Cancer survival in southern African urban population. A Gondos E Chokunonga H Brenner DM Parkin R Sankila MZ Borok ZM Chirenje AM Nyakabau MT Bassett, Int J Cancer 2004 112 860 864 10.1002/ijc.20471 15386382
9. Attempts to detect virus-specific DNA sequences in human tumors: I. Nucleic acid hybridization with complementary RNA of human wart virus. H zur Hausen W Meinhof W Scheiber GW Bornkamm, Int J Cancer 1974 13 650 656 10.1002/ijc.2910130509 4367340
10. Classification of papillomaviruses. EM de Villiers C Fauquet TR Broker HU Bernard H zur Hausen, Virology 2004 324 17 27 10.1016/j.virol.2004.03.033 15183049
11. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Munoz FX Bosch S de Sanjose R Herrero X Castellsague KV Shah PJ Snijders CJ Meijer International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259
12. HPV in the etiology of human cancer. N Munoz X Castellsague AB de Gonzalez L Gissmann, Vaccine 2006 24 Suppl 3 S1 S10 10.1016/j.vaccine.2006.05. 115
13. HPV type distribution in women with and without cervical neoplastic diseases. G Clifford S Franceschi M Diaz N Munoz LL Villa, Vaccine 2006 24 Suppl 3 S26 34 10.1016/j.vaccine.2006.05.026
14. The epidemiology of genital human papillomavirus infection. H Trottier EL Franco, Vaccine 2006 24 Suppl 1 S1 S15 16406226
15. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Mũoz, J Pathol 1999 189 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
16. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. JS Smith L Lindsay B Hoots J Keys S Franceschi R Winer GM Clifford, Int J Cancer 2007 121 621 632 10.1002/ijc.22527 17405118
17. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. GM Clifford RK Rana S Franceschi JS Smith G Gough JM Pimenta, Cancer Epidemiol Biomarkers Prev 2005 14 1157 1164 10.1158/1055-9965.EPI-04-0812 15894666
18. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. S de Sanjosé M Diaz X Castellsagué G Clifford L Bruni N Mũoz FX Bosch, Lancet Infect Dis 2007 7 453 459 10.1016/S1473-3099(07)70158-5 17597569
19. Prevalence of human papillomavirus infection in women in Turin, Italy. G Ronco V Ghisetti N Segnan PJ Snijders A Gillio-Tos CJ Meijer F Merletti S Franceschi, Eur J Cancer 2005 41 297 305 10.1016/j.ejca.2004.07.005 15661556
20. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. ML Tornesello ML Duraturo G Botti S Greggi R Piccoli G De Palo M Montella L Buonaguro FM Buonaguro Italian HPV Working Group, J Med Virol 2006 78 1663 1672 10.1002/jmv.20752 17063505
21. Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. S Menzo A Ciavattini P Bagnarelli K Marinelli S Sisti M Clementi, BMC Microbiology 2008 8 112 18601724 10.1186/1471-2180-8-112
22. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. N Munoz FX Bosch X Castellsague M Diaz S de Sanjose D Hammouda KV Shah CJ Meijer, Int J Cancer 2004 111 278 285 10.1002/ijc.20244 15197783
23. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. G Ronco P Giorgi-Rossi F Carozzi M Confortini P Dalla Palma A Del Mistro A Gillio-Tos D Minucci C Naldoni R Rizzolo P Schincaglia R Volante M Zappa M Zorzi J Cuzick N Segnan New Technologies for Cervical Cancer Screening Working Group, J Natl Cancer Inst 2008 100 492 501 10.1093/jnci/djn065 18364502
24. Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy. P Ammatuna L Giovannelli D Matranga S Ciriminna A Perino, Cancer Epidemiol Biomarkers Prev 2008 17 2002 2006 10.1158/1055-9965.EPI-08-0180 18708390
25. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. SK Kiær G Breugelmans C Munk J Junge M Watson T Iftner, Int J Cancer 2008 123 1864 1870 10.1002/ijc.23712 18661520
26. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer. The EDiTH III study. J-L Prétet A-C Jacquard M Saunier C Clavel R Dachez J Gondry P Pradat B Soubeyrand Y Leocmach C Mougin D Riethmuller for the EDiTH study group, Gynecol Oncol 2008 110 179 184 10.1016/j.ygyno.2008.04.012 18514800
27. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. J-L Pretet A-C Jacquard X Carcopino S Monnier-Benoit G Averous B Soubeyrand Y Leocmach C Mougin D Riethmuller for the EDITH study group, Int J Cancer 2008 122 424 427 10.1002/ijc.23093 17893883
28. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. J-L Pretet A-C Jacquard X Carcopino j-F Charlot D Bouhour B Kantelip B Soubeyrand Y Leocmach C Mougin D Riethmuller for the EDITH study group, Int J Cancer 2008 122 428 432 10.1002/ijc.23092 17893882
29. Papillomaviruses and cancer: from basic studies to clinical application. H zur Hausen, Nat Rev Cancer 2002 2 342 350 10.1038/nrc798 12044010
30. Case-control study of human papillomavirus and oropharyngeal cancer. G D'Souza AR Kreimer R Viscidi M Pawlita C Fakhry WM Koch WH Westra ML Gillison, N Engl J Med 2007 356 1944 1956 10.1056/NEJMoa065497 17494927
31. Human papillomavirus genotypes and HPV16 variants in penile carcinoma. ML Tornesello ML Duraturo S Losito G Botti S Pilotti B Stefanon G De Palo A Gallo L Buonaguro FM Buonaguro, Int J Cancer 2008 122 132 137 10.1002/ijc.23062 17764110
32. Molecular biology of human papillomavirus infection and cervical cancer. J Doorbar, Clin Sci 2006 110 525 541 10.1042/CS20050369 16597322
33. Papillomaviruses. PM Howley DR Lowy, Fields Virology Lippincott Williams & Wilkins Philadelphia, PA, USA, Knipe DM, Howley PM, 5 2007
34. The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication. JS Liu SR Kuo TR Broker LT Chow, J Biol Chem 1995 270 27283 27291 10.1074/jbc.270.45.27283 7592989
35. Transactivation of a bovine papillomavirus transcriptional regulatory element by the E2 gene product. BA Spalholz YC Yang PM Howley, Cell 1985 42 183 191 10.1016/S0092-8674(85)80114-8 2990724
36. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. BA Bernard C Bailly MC Lenoir M Darmon F Thierry M Yaniv, J Virol 1989 63 4317 4324 2476572
37. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. J Doorbar S Ely J Sterling C McLean L Crawford, Nature 1991 352 824 827 10.1038/352824a0 1715519
38. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. M Conrad Vj Bubb R Schleger, J Virol 1993 67 6170 6178 7690419
39. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. SW Straight B Herman DJ McCance, J Virol 1995 69 3185 3192 7707548
40. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. EC Goodwin LK Naeger DE Breiding EJ Androphy D DiMaio, J Virol 1998 72 3925 3934 9557678
41. Interaction of HPV E6 and E7 with tumor suppressor gene products. K Münger M Scheffner JM Huibregtse PM Howley, Cancer Surv 1992 12 197 217 1322242
42. The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. N Dyson PM Howley K Münger E Harlow, Science 1989 243 934 937 10.1126/science.2537532 2537532
43. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. SN Boyer DE Wazer V Band, Cancer Res 1996 56 4620 4624 8840974
44. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. K Zerfass-Thome W Zwerschke B Mannhardt R Tindle JW Botz P Jansen-Dürr, Oncogene 1996 13 2323 2330 8957073
45. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. JO Funk S Waga JB Harry E Espling B Stillman DA Galloway, Genes Dev 1997 11 2090 2100 9284048 10.1101/gad.11.16.2090
46. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. DL Jones RM Alani K Münger, Genes Dev 1997 11 2101 2111 9284049 10.1101/gad.11.16.2101
47. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. S Duensing K Münger, Proc Natl Acad Sci USA 2000 97 10002 10007 10944189 10.1073/pnas.170093297
48. Association of human papillomavirus types 16 and 18 E6 proteins with p53. BA Werness AJ Levine PM Howley, Science 1990 248 76 79 10.1126/science.2157286 2157286
49. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. M Scheffner JM Huibregtse RD Vierstra PM Howley, Cell 1993 75 495 505 10.1016/0092-8674(93)90384-3 8221889
50. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. E Schwarz UK Freese L Gissmann W Mayer B Roggenbuck A Stremlau H zur Hausen, Nature 1985 314 111 114 10.1038/314111a0 2983228
51. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. S Jeon PF Lambert, Proc Natl Acad Sci USA 1995 92 1654 1658 7878034 10.1073/pnas.92.5.1654
52. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. AM Kersemaekers MJ van de Vijver GG Kenter GJ Fleuren, Genes Chromosomes Cancer 1999 26 346 354 10.1002/(SICI)1098-2264(199912)26: 4<346::AID-GCC9>3.0.CO;2-D 10534770
53. American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. D Saslow CD Runowicz D Solomon AB Moscicki RA Smith HJ Eyre C Cohen American Cancer Society, CA Cancer J Clin 2002 52 342 362 12469763
54. Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects. RA Smith V Cokkinides HJ Eyre, CA Cancer J Clin 2007 57 90 104 17392386
55. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. TC Wright Jr LS Massad CJ Dunton M Spitzer EJ Wilkinson D Solomon 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference, Am J Obstet Gynecol 2007 197 346 355 10.1016/j.ajog.2007.07.047 17904957
56. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. TC Wright Jr LS Massad CJ Dunton M Spitzer EJ Wilkinson D Solomon 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference, Am J Obstet Gynecol 2007 197 340 345 10.1016/j.ajog.2007.07.050 17904956
57. Council Recommendation of 2 December on Cancer Screening. Council of the European Union, Off J Eur Union 2003 878 34 38
58. European guidelines for quality assurance in cervical cancer screening. M Arbyn A Anttila J Jordan G Ronco U Schenck N Segnan HG Wiener A Herbert J Daniel L von Karsa, Luxembourg: Office for Official Publications of the European Communities Second 2008
59. Raccomandazioni per la pianificazione e l'esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon retto. Ministero della Salute, Direzione Generale della Prevenzione, 2006
60. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. K Nanda DC McCrory ER Myers LA Bastian V Hasselblad JD Hickey DB Matchar, Ann Intern Med 2000 132 810 819 10819705
61. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. M Arbyn F Buntinx M Van Ranst E Paraskevaidis P Martin-Hirsch J Dillner, J Natl Cancer Inst 2004 96 280 293 14970277
62. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. J Cuzick C Clavel K-U Petry CJLM Meijer H Hoyer S Ratnam A Szarewski P Birembaut S Kulasingam P Sasieni T Iftner, Int J Cancer 2006 119 1095 1101 10.1002/ijc.21955 16586444
63. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. G Koliopoulos M Arbyn P Martin-Hirsch M Kyrgiou W Prendiville E Paraskevaidis, Gynecol Oncol 2007 104 232 246 10.1016/j.ygyno.2006.08.053 17084886
64. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. MH Stoler M Schiffman for the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group, JAMA 2001 285 1500 1505 10.1001/jama.285.11.1500 11255427
65. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. M Arbyn P Sasieni CJ Meijer C Clavel G Koliopoulos J Dillner, Vaccine 2006 24 S3 78 89 10.1016/j.vaccine.2006.05.117
66. Direct comparison of liquid-based and conventional cytology in a south African screening trial. S Taylor L Kuhn W Dupree L Denny M De Souza TC Wright Jr, Int J Cancer 2006 118 957 962 10.1002/ijc.21434 16152600
67. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. G Ronco J Cuzick P Pierotti MP Cariaggi P Dalla Palma C Naldoni B Ghiringhello P Giorgi-Rossi D Minucci F Parisio A Pojer ML Schiboni C Sintoni M Zorzi N Segnan M Confortini, BMJ 2007 335 28 17517761 10.1136/bmj.39196.740995.BE
68. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. D Solomon M Schiffman R Tarone ALTS Study group, J Natl Cancer Inst 2001 93 293 299 10.1093/jnci/93.4.293 11181776
69. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). SL Kulasingam JJ Kim WF Lawrence JS Mandelblatt ER Myers M Schiffman D Solomon SJ Goldie ALTS Group, J Natl Cancer Inst 2006 98 92 100 16418511
70. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. M Arbyn E Paraskevaidis P Martin-Hirsch W Prendiville J Dillner, Gynecol Oncol 2005 99 Suppl 3 7 11 10.1016/j.ygyno.2005.07.033
71. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. ALTS group, J Natl Cancer Inst 2000 92 397 402 10.1093/jnci/92.5.397 10700419
72. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. G Ronco J Cuzick N Segnan S Brezzi F Carozzi S Folicaldi P Dalla Palma A Del Mistro A Gillio-Tos P Giubilato C Naldoni E Polla A Iossa M Zorzi M Confortini P Giorgi-Rossi NTCC working group, Eur J Cancer 2007 43 476 480 10.1016/j.ejca.2006.11.013 17223540
73. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. V Houfflin Debarge P Collinet D Vinatier A Ego A Dewilde F Boman JL Leroy, Gynecol Oncol 2003 90 587 592 10.1016/S0090-8258(03)00372-X 13678729
74. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. E Paraskevaidis M Arbyn A Sotiriadis E Diakomanolis P Martin-Hirsch G Koliopoulos G Makrydimas J Tofoski DH Roukos, Cancer Treat Rev 2004 30 205 211 10.1016/j.ctrv.2003.07.008 15023438
75. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. AR Kreimer RS Guido D Solomon M Schiffman S Wacholder J Jeronimo CM Wheeler PE Castle, Cancer Epidemiol Biomarkers Prev 2006 15 908 914 10.1158/1055-9965.EPI-05-0845 16702369
76. HPV testing and monitoring of women after treatment of CIN3: review of the literature and meta-analysis. GD Zielinski AG Bais TJ Helmerhorst RH Verheijen FA de Schipper PJ Snijders FJ Voorhorst FJ van Kemenade L Rozendaal CJ Meijer, Obstet Gynecol Surv 2004 59 543 553 10.1097/00006254-200407000-00024 15199273
77. Primary screening of cervical cancer with human papillomavirus tests. EL Franco, J Natl Cancer Inst Monogr 2003 31 89 96 12807951
78. Management of women who test positive for high-risk types of human papillomavirus: the HART study. J Cuzick A Szarewski H Cubie G Hulman H Kitchener D Luesley E McGoogan U Menon G Terry R Edwards C Brooks M Desai C Gie L Ho I Jacobs C Pickles P Sasieni, Lancet 2003 362 1871 1876 10.1016/S0140-6736(03)14955-0 14667741
79. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. P Davies M Arbyn J Dillner HC Kitchener CJ Meijer G Ronco M Hakama, Int J Cancer 2006 118 791 796 10.1002/ijc.21611 16287075
80. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. G Ronco N Segnan P Giorgi-Rossi M Zappa GP Casadei F Carozzi P Dalla Palma A Del Mistro S Folicaldi A Gillio-Tos G Nardo C Naldoni P Schincaglia M Zorzi M Confortini J Cuzick New Technologies for Cervical Cancer Working Group, J Natl Cancer Inst 2006 98 765 774 16757701
81. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. G Ronco P Giorgi-Rossi F Carozzi P Dalla Palma A Del Mistro L De Marco M De Lillo C Naldoni P Pierotti R Rizzolo N Segnan P Schincaglia M Zorzi M Confortini J Cuzick New Technologies for Cervical Cancer screening Working Group, Lancet Oncol 2006 7 547 555 10.1016/S1470-2045(06) 70731-8 16814206
82. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. P Dalla Palma P Giorgi Rossi G Collina AM Buccoliero B Ghiringhello M Lestani G Onnis D Aldovini G Galanti G Casadei M Aldi V Gomes P Giubilato G Ronco NTCC Pathology Group, Am J Clin Pathol 2008 129 75 80 10.1309/EWYGWFRRM8798U5P 18089491
83. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. NWJ Bulkmans J Berkhof L Rozendaal FJ van Kemenade AJP Boeke S Bulk FJ Voorhorst RHM Verheijen K van Groningen ME Boon W Ruitinga M van Ballegooijen PJF Snijders CJLM Meijer, Lancet 2007 370 1764 1772 10.1016/S0140-6736(07)61450-0 17919718
84. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. P Naucler W Ryd S Törnberg A Strand G Wadell K Elfgren T Rådberg B Strander O Forslund B-G Hansson E Rylander J Dillner, N Engl J Med 2007 357 1589 1597 10.1056/NEJMoa073204 17942872
85. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. ME Sherman AT Lorincz DR Scott S Wacholder PE Castle AG Glass I Mielzynska-Lohnas BB Rush M Schiffman, J Natl Cancer Inst 2003 95 46 52 12509400
86. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. M-H Mayrand E Duarte-Franco I Rodrigues SD Walter J Hanley A Ferenczy S Ratnam F Coutlée EL Franco for the Canadian Cervical Cancer Screening Trial Study Group, N Engl J Med 2007 357 1579 1588 10.1056/NEJMoa071430 17942871
87. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. MA Nobbenhuis TJ Helmerhorst AJ van den Brule L Rozendaal FJ Voorhorst PD Bezemer RH Verheijen CJ Meijer, Lancet 2001 358 1782 1783 10.1016/S0140-6736(01)06809-X 11734239
88. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. AJ Remmink JM Walboomers TJ Helmerhorst FJ Voorhorst L Rozendaal EK Risse CJ Meijer P Kenemans, Int J Cancer 1995 61 306 311 10.1002/ijc.2910610305 7729939
89. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. GY Ho RD Burk S Klein AS Kadish CJ Chang P Palan J Basu R Tachezy R Lewis S Romney, J Natl Cancer Inst 1995 87 1365 1371 10.1093/jnci/87.18.1365 7658497
90. Natural history of cervicovaginal papillomavirus infection in young women. GY Ho R Bierman L Beardsley CJ Chang RD Burk, N Engl J Med 1998 338 423 428 10.1056/NEJM199802123380703 9459645
91. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. MA Nobbenhuis JM Walboomers TJ Helmerhorst L Rozendaal AJ Remmink EK Risse HC van der Linden FJ Voorhorst P Kenemans CJ Meijer, Lancet 1999 354 20 25 10.1016/S0140-6736(98) 12490-X 10406360
92. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. V Dalstein D Riethmuller JL Prétet K Le Bail Carval JL Sautière JP Carbillet B Kantelip JP Schaal C Mougin, Int J Cancer 2003 106 396 403 10.1002/ijc.11222 12845680
93. High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. A Gingelmaier T Grubert R Kaestner I Mylonas T Weissenbacher F Bergauer L Barthell K Friese, Anticancer Res 2007 27 1795 1798 17649775
94. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. JP Bory J Cucherousset M Lorenzato R Gabriel C Quereux P Birembaut C Clavel, Int J Cancer 2002 102 519 525 10.1002/ijc.10735 12432556
95. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. AG Bais M Rebolj PJ Snijders FA de Schipper DA van der Meulen RH Verheijen F Voorhorst M van Ballegooijen CJ Meijer TJ Helmerhorst, Int J Cancer 2005 116 122 129 10.1002/ijc.20958 15751045
96. The carcinogenicity of human papillomavirus types reflects viral evolution. M Schiffman R Herrero R Desalle A Hildesheim S Wacholder AC Rodriguez MC Bratti ME Sherman J Morales D Guillen M Alfaro M Hutchinson TC Wright D Solomon Z Chen J Schussler PE Castle RD Burk, Virology 2005 337 76 84 10.1016/j.virol.2005.04.002 15914222
97. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. I Kraus T Molden R Holm AK Lie F Karlsen GB Kristensen H Skomedal, J Clin Microbiol 2006 44 1310 1317 16597856 10.1128/JCM.44.4.1310-1317.2006
98. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. T Molden I Kraus F Karlsen H Skomedal JF Nygard B Hagmar, Cancer Epidemiol Biomarkers Prev 2005 14 367 372 10.1158/1055-9965.EPI-04-0410 15734959
99. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. T Molden JF Nygard I Kraus F Karlsen M Nygard GB Skare H Skomedal SO Thoresen B Hagmar, Int J Cancer 2005 114 973 976 10.1002/ijc.20839 15645423
100. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. MA de Boer ES Jordanova GG Kenter AA Peters WE Corver JB Trimbos GJ Fleuren, Clin Cancer Res 2007 13 132 138 10.1158/1078-0432.CCR-06-1568 17200347
101. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. PE Castle J Dockter C Giachetti FA Garcia MK McCormick AL Mitchell EB Holladay DP Kolk, Clin Cancer Res 2007 13 2599 2605 10.1158/1078-0432.CCR-06-2881 17473189
102. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. AM Josefsson PK Magnusson N Ylitalo P Sorensen P Qwarforth-Tubbin PK Andersen M Melbye HO Adami UB Gyllensten, Lancet 2000 355 2189 2193 10.1016/S0140-6736(00)02401-6 10881891
103. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. N Ylitalo P Sorensen AM Josefsson PK Magnusson PK Andersen J Ponten HO Adami UB Gyllensten M Melbye, Lancet 2000 355 2194 2198 10.1016/S0140-6736(00)02402-8 10881892
104. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: a study in Chinese population. KW Lo SW Yeung TH Cheung NS Siu T Kahn YF Wong, J Clin Virol 2005 34 76 80 10.1016/j.jcv.2005.05.006 16002332
105. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. M Moberg I Gustavsson E Wilander U Gyllensten, Br J Cancer 2005 92 891 894 10.1038/sj.bjc.6602436 15756259
106. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. AN Fiander KW Hart SJ Hibbitts GC Rieck AJ Tristram RW Beukenholdt NG Powell, J Med Virol 2007 79 1366 1369 10.1002/jmv.20875 17607770
107. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. AT Lorincz PE Castle ME Sherman DR Scott AG Glass S Wacholder BB Rush PE Gravitt JE Schussler M Schiffman, Lancet 2002 360 228 229 10.1016/S0140-6736(02)09463-1 12133661
108. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. R Flores M Papenfuss WT Klimecki AR Giuliano, Int J Cancer 2006 118 1187 1193 10.1002/ijc.21477 16152619
109. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. PJ Snijders CJ Hogewoning AT Hesselink J Berkhof FJ Voorhorst MC Bleeker CJ Meijer, Int J Cancer 2006 119 1102 1107 10.1002/ijc.21956 16570279
110. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. LA Koutsky KK Holmes CW Critchlow CE Stevens J Paavonen AM Beckmann TA DeRouen DA Galloway D Vernon NB Kiviat, N Engl J Med 1992 327 1272 1278 1328880
111. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. MJ Khan PE Castle AT Lorincz S Wacholder M Sherman DR Scott BB Rush AG Glass M Schiffman, J Natl Cancer Inst 2005 97 1072 1079 16030305
112. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. PE Castle D Solomon M Schiffman CM Wheeler, J Natl Cancer Inst 2005 97 1066 1071 16030304
113. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. X Castellsague M Diaz S de Sanjose N Munoz R Herrero S Franceschi RW Peeling R Ashley JS Smith PJ Snijders CJ Meijer FX Bosch International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, J Natl Cancer Inst 2006 98 303 315 16507827
114. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. RE Zuna RA Allen WE Moore Y Lu R Mattu ST Dunn, Mod Pathol 2007 20 167 174 10.1038/modpathol.3800723 17192793
115. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. M Guo N Sneige EG Silva YJ Jan DE Cogdell E Lin R Luthra W Zhang, Mod Pathol 2007 20 256 266 10.1038/modpathol.3800737 17192787
116. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Berumen RM Ordõez E Lazcano J Salmeron SC Galvan RA Estrada E Yunes A Garcia-Carranca G Gonzalez-Lira A Madrigal-de la Campa, J Natl Cancer Inst 2001 93 1325 1330 10.1093/jnci/93.17.1325 11535707
117. Human papillomavirus type 16 variants and risk of cervical cancer. A Hildesheim M Schiffman C Bromley S Wacholder R Herrero A Rodriguez MC Bratti ME Sherman U Scarpidis QQ Lin M Terai RL Bromley K Buetow RJ Apple RD Burk, J Natl Cancer Inst 2001 93 315 318 10.1093/jnci/93.4.315 11181779
118. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. L Sichero S Ferreira H Trottier E Duarte-Franco A Ferenczy EL Franco LL Villa, Int J Cancer 2007 120 1763 1768 10.1002/ijc.22481 17230525
119. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. I Zehbe E Wilander H Delius M Tommasino, Cancer Res 1998 58 829 833 9485042
120. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. CS Brady MF Duggan-keen JA Davidson JM Varley PL Stern, J Gen Virol 1999 80 3233 3240 10567656
121. Human papillomavirus Type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by Notch signaling and oncogenic ras. O Chakrabarti K Veeraraghavalu V Tergaonkar Y Liu EJ Androphy MA Stanley S Krishna, J Virol 2004 78 5934 5945 15140991 10.1128/JVI.78.11.5934-5945.2004
122. Variable oncogene promoter activity of human papillomavirus type 16 cervical cancer isolates from Australia. KJ Watts CH Thompson YE Cossart BR Rose, J Clin Microbiol 2001 39 2009 2014 11326037 10.1128/JCM.39.5.2009-2014. 2001
123. Sequence variation and physical state of human papillomavirus type 16 cervical cancer isolates from Australia and New Caledonia. KJ Watts CH Thompson YE Cossart BR Rose, Int J Cancer 2002 97 868 874 10.1002/ijc.10103 11857370
124. A study of the impact of adding HPV types to cervical cancer screening and triage tests. M Schiffman MJ Khan D Solomon R Herrero S Wacholder A Hildesheim AC Rodriguez MC Bratti CM Wheeler RD Burk PEG Group; ALTS Group, J Natl Cancer Inst 2005 97 147 50 15657345
125. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. P Naucler W Ryd S Törnberg A Strand G Wadell BG Hansson E Rylander J Dillner, Br J Cancer 2007 97 129 132 10.1038/sj.bjc.6603843 17551490
126. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. SD Vernon ER Unger DL Miller DR Lee WC Reeves, Int J Cancer 1997 74 50 56 10.1002/(SICI)1097- 0215(19970220)74:1<50::AID-IJC9>3.0.CO;2-# 9036869
127. Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. M Kalantari F Karlsen G Kristensen R Holm B Hagmar B Johansson, Int J Gynecol Pathol 1998 17 146 153 9553812
128. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. R Klaes T Friedrich D Spitkovsky R Ridder W Rudy U Petry G Dallenbach-Hellweg D Schmidt DM von Knebel, Int J Cancer 2001 92 276 284 10.1002/ijc.1174 11291057
129. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. C Mao A Balasubramanian M Yu N Kiviat R Ridder A Reichert M Herkert M von Knebel Doeberitz LA Koutsky, Int J Cancer 2007 120 2435 2438 10.1002/ijc.22612 17294450
130. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. SS Wang M Trunk M Schiffman R Herrero ME Sherman RD Burk A Hildesheim MC Bratti T Wright AC Rodriguez S Chen A Reichert C von Knebel Doeberitz R Ridder M von Knebel Doeberitz, Cancer Epidemiol Biomarkers Prev 2004 13 1355 1360 15298958
131. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. EB Holladay S Logan J Arnold B Knesel GD Smith, Cancer 2006 108 451 461 10.1002/cncr.22284 17078096
132. p16INK4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. R Klaes A Benner T Friedrich R Ridder S Herrington D Jenkins RJ Kurman D Schmidt M Stoler DM von Knebel, Am J Surg Pathol 2002 26 1389 1399 10.1097/00000478-200211000-00001 12409715
133. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. F Carozzi M Confortini PD Palma A Del Mistro A Gillio-Tos L De Marco P Giorgi-Rossi G Pontenani S Rosso C Sani C Sintoni N Segnan M Zorzi J Cuzick R Rizzolo G Ronco the New Technologies for Cervival Cancer screening (NTCC) working group, Lancet Oncol 9 10 937 945 10.1016/S1470-2045(08)70208-0 18783988
134. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. GY Ho YY Studentsov CB Hall R Bierman L Beardsley M Lempa RD Burk, J Infect Dis 2002 186 737 742 10.1086/342972 12198606
135. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. GY Ho YY Studentsov R Bierman RD Burk, Cancer Epidemiol Biomarkers Prev 2004 13 110 116 10.1158/1055-9965.EPI-03-0191 14744741
136. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Dillner M Lehtinen T Bjorge T Luostarinen L Youngman E Jellum P Koskela RE Gislefoss G Hallmans J Paavonen M Sapp JT Schiller T Hakulinen S Thoresen M Hakama, J Natl Cancer Inst 1997 89 1293 1299 10.1093/jnci/89.17.1293 9293920
137. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. MH Einstein YY Studentsov GY Ho M Fazzari M Marks AS Kadish GL Goldberg CD Runowicz RD Burk, Int J Cancer 2006 120 55 59 10.1002/ijc.22176
138. Human papillomavirus technologies. T Iftner LL Villa, J Natl Cancer Inst Monogr 2003 31 80 88 12807950
139. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. RZ Rizk ND Christensen KM Michael M Müller P Sehr T Waterboer M Pawlita, J Gen Virol 2008 89 117 129 10.1099/vir.0.83145-0 18089735
140. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. A de Jong MI van Poelgeest JM van der Hulst JW Drijfhout GJ Fleuren CJ Melief G Kenter R Offringa SH van der Burg, Cancer Res 2004 64 5449 5455 10.1158/0008-5472.CAN-04- 0831 15289354
141. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. SJ Piersma ES Jordanova MI van Poelgeest KM Kwappenberg JM van der Hulst JW Drijfhout CJ Melief GG Kenter GJ Fleuren R Offringa SH van der Burg, Cancer Res 2007 67 354 361 10.1158/0008-5472.CAN-06- 3388 17210718
142. A controlled trial of a human papillomavirus type 16 vaccine. LA Koutsky KA Ault CM Wheeler DR Brown E Barr FB Alvarez LM Chiacchierini KU Jansen Proof of Principle Study Investigators, N Engl J Med 2002 347 1645 1651 10.1056/NEJMoa020586 12444178
143. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. C Mao LA Koutsky KA Ault CM Wheeler DR Brown DJ Wiley FB Alvarez OM Bautista KU Jansen E Barr, Obstet Gynecol 2006 107 18 27 16394035
144. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human Papillomavirus types 16 and 18 in young women: a randomised controlled trial. DM Harper EL Franco C Wheeler DG Ferris D Jenkins A Schuind T Zahaf B Innis P Naud NS De Carvalho CM Roteli-Martins J Teixeira MM Blatter AP Korn W Quint G Dubin GlaxoSmithKline HPV Vaccine Study Group, Lancet 2004 364 1757 1765 10.1016/S0140-6736(04)17398-4 15541448
145. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins D Jenkins A Schuind SA Costa Clemens G Dubin HPV Vaccine Study group, Lancet 2006 367 1247 1255 10.1016/S0140-6736(06)68439-0 16631880
146. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. J Paavonen D Jenkins FX Bosch P Naud J Salmerón CM Wheeler SN Chow DL Apter HC Kitchener X Castellsague NS de Carvalho SR Skinner DM Harper JA Hedrick U Jaisamrarn GA Limson M Dionne W Quint B Spiessens P Peeters F Struyf SL Wieting MO Lehtinen G Dubin HPV PATRICIA study group, Lancet 2007 369 2161 2170 10.1016/S0140-6736(07)60946-5 17602732
147. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. LL Villa RL Costa CA Petta RP Andrade J Paavonen OE Iversen SE Olsson J Hoye M Steinwall G Riis-Johannessen A Andersson-Ellstrom K Elfgren G Krogh M Lehtinen C Malm GM Tamms K Giacoletti L Lupinacci R Railkar FJ Taddeo J Bryan MT Esser HL Sings AJ Saah E Barr, Br J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182
148. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. FUTURE II Study Group, N Engl J Med 2007 356 1915 1927 10.1056/NEJMoa061741 17494925
149. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. SM Garland M Hernandez-Avila CM Wheeler G Perez DM Harper S Leodolter GW Tang DG Ferris M Steben J Bryan FJ Taddeo R Railkar MT Esser HL Sings M Nelson J Boslego C Sattler E Barr LA Koutsky Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators, N Engl J Med 2007 356 1928 1943 10.1056/NEJMoa061760 17494926
150. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. SL Giannini E Hanon P Moris M Van Mechelen S Morel F Dessy MA Fourneau B Colau J Suzich G Losonksy MT Martin G Dubin MA Wettendorff, Vaccine 2006 24 5937 5949 10.1016/j.vaccine.2006.06.005 16828940
151. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. C Pedersen T Petaja G Strauss HC Rumke A Poder JH Richardus B Spiessens D Descamps K Hardt M Lehtinen G Dubin HPV Vaccine Adolescent Study Investigators Network, J Adolesc Health 2007 40 564 571 10.1016/j.jadohealth.2007.02.015 17531764
152. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. LL Villa RL Costa CA Petta RP Andrade KA Ault AR Giuliano CM Wheeler LA Koutsky C Malm M Lehtinen FE Skjeldestad SE Olsson M Steinwall DR Brown RJ Kurman BM Ronnett MH Stoler A Ferenczy DM Harper GM Tamms J Yu L Lupinacci R Railkar FJ Taddeo KU Jansen MT Esser HL Sings AJ Saah E Barr, Lancet Oncol 2005 6 271 278 10.1016/S1470- 2045(05)70101-7 15863374
153. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. SE Olsson LL Villa RL Costa CA Petta RP Andrade C Malm OE Iversen J Hoye M Steinwall G Riis-Johannessen A Andersson-Ellstrom K Elfgren G von Krogh M Lehtinen J Paavonen GM Tamms K Giacoletti L Lupinacci MT Esser SC Vuocolo AJ Saah E Barr, Vaccine 2007 25 4931 4939 10.1016/j.vaccine.2007.03.049 17499406
154. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. SL Block T Nolan C Sattler E Barr KE Giacoletti CD Marchant X Castellsagué SA Rusche S Lukac JT Bryan PF Cavanaugh Jr KS Reisinger Protocol 016 Study Group, Pediatrics 2006 118 2135 2145 10.1542/peds.2006-0461 17079588
155. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. KS Reisinger SL Block E Lazcano-Ponce R Samakoses MT Esser J Erick D Puchalski KE Giacoletti HL Sings S Lukac FB Alvarez E Barr, Pediatr Infect Dis J 2007 26 201 209 10.1097/01.inf.0000253970.29190.5a 17484215
156. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. EA Joura S Leodolter M Hernandez-Avila CM Wheeler G Perez LA Koutsky SM Garland DM Harper GW Tang DG Ferris M Steben RW Jones J Bryan FJ Taddeo OM Bautista MT Esser HL Sings M Nelson JW Boslego C Sattler E Barr J Paavonen, Lancet 2007 369 1693 1702 10.1016/S0140-6736(07)60777-6 17512854
157. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. KA Ault Future II Study Group, Lancet 2007 369 1861 1868 10.1016/S0140-6736(07) 60852-6 17544766
158. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. A Hildesheim R Herrero S Wacholder AC Rodriguez D Solomon MC Bratti JT Schiller P Gonzales G Dubin C Porras SE Jimenez DR Lowy for the Costa Rican HPV Vaccine Trial Group, JAMA 2007 298 743 753 10.1001/jama.298.7.743 17699008
159. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. FUTURE II Study Group, J Infect Dis 2007 196 1438 1446 10.1086/522864 18008221
160. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. D Jenkins, Gynecol Oncol 2008 110 S18 S25 10.1016/j.ygyno.2008.06.027 18653221
161. Prophylactic HPV vaccines: New interventions for cancer control. E Barr HL Sings, Vaccine 2008 26 6244 6257 10.1016/j.vaccine.2008.07.056 18694795